Veritas Pharma Stock Current Liabilities
| VRTHF Stock | USD 0 0.00 0.00% |
Veritas Pharma fundamentals help investors to digest information that contributes to Veritas Pharma's financial success or failures. It also enables traders to predict the movement of Veritas Pink Sheet. The fundamental analysis module provides a way to measure Veritas Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Veritas Pharma pink sheet.
Veritas |
Veritas Pharma Company Current Liabilities Analysis
Veritas Pharma's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, Veritas Pharma has a Current Liabilities of 0.0. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Veritas Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Veritas Pharma's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Veritas Pharma could also be used in its relative valuation, which is a method of valuing Veritas Pharma by comparing valuation metrics of similar companies.Veritas Pharma is currently under evaluation in current liabilities category among its peers.
Veritas Fundamentals
| Return On Equity | -5.67 | |||
| Return On Asset | -0.21 | |||
| Current Valuation | 1.77 M | |||
| Shares Outstanding | 71.14 M | |||
| Shares Owned By Insiders | 27.34 % | |||
| Price To Earning | 0.20 X | |||
| Price To Book | 0.43 X | |||
| Gross Profit | (112.96 K) | |||
| EBITDA | (491.67 K) | |||
| Net Income | (2.29 M) | |||
| Cash And Equivalents | 125.27 K | |||
| Total Debt | 765.63 K | |||
| Debt To Equity | 0.05 % | |||
| Current Ratio | 0.64 X | |||
| Book Value Per Share | (0.04) X | |||
| Cash Flow From Operations | (294.86 K) | |||
| Earnings Per Share | (0.03) X | |||
| Beta | -0.0588 | |||
| Market Capitalization | 1.59 M | |||
| Total Asset | 730 | |||
| Net Asset | 730 |
About Veritas Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Veritas Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Veritas Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Veritas Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Veritas Pink Sheet
Veritas Pharma financial ratios help investors to determine whether Veritas Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Veritas with respect to the benefits of owning Veritas Pharma security.